Harold Neal Keer

5PUBLICATIONS
25CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 31, 2025
Decitabine-cedazuridine in patients with MDS and TP53 mutations.

Samuel Urrutia, Koji Sasaki, Alex Bataller

|Jun 17, 2025
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.

Michael R Savona, Olatoyosi Odenike, Gail J Roboz

|Sep 24, 2024
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.

Klaus Geissler, Zdenek Koristek, Teresa Bernal Del Castillo

|May 10, 2024
Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma.

George A Ward, Zhiqiang Zhang, Simone Jueliger

|Dec 08, 2020
Methylomic Signatures of High Grade Serous Ovarian Cancer.

Horacio Cardenas, Fang Fang, Guanglong Jiang

Pageof 1